Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Systematic review of the clinical and genetic aspects of Prader-Willi syndrome

  • Jin, Dong-Kyu (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2011.01.06
  • Accepted : 2011.01.31
  • Published : 2011.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Prader-Willi syndrome (PWS) is a complex multisystem genetic disorder that is caused by the lack of expression of paternally inherited imprinted genes on chromosome 15q11-q13. This syndrome has a characteristic phenotype including severe neonatal hypotonia, early-onset hyperphagia, development of morbid obesity, short stature, hypogonadism, learning disabilities, behavioral problems, and psychiatric problems. PWS is an example of a genetic condition caused by genomic imprinting. It can occur via 3 main mechanisms that lead to the absence of expression of paternally inherited genes in the 15q11.2-q13 region: paternal microdeletion, maternal uniparental disomy, and an imprinting defect. Over 99% of PWS cases can be diagnosed using DNA methylation analysis. Early diagnosis of PWS is important for effective long-term management. Growth hormone (GH) treatment improves the growth, physical phenotype, and body composition of patients with PWS. In recent years, GH treatment in infants has been shown to have beneficial effects on the growth and neurological development of patients diagnosed during infancy. There is a clear need for an integrated multidisciplinary approach to facilitate early diagnosis and optimize management to improve quality of life, prevent complications, and prolong life expectancy in patients with PWS.

Keywords

References

  1. Driscoll DJ, Waters MF, Williams CA, Zori RT, Glenn CC, Avidano KM, et al. A DNA methylation imprint, determined by the sex of the parent, distinguishes the Angelman and Prader-Willi syndromes. Genomics 1992;13:917-24. https://doi.org/10.1016/0888-7543(92)90001-9
  2. Nicholls RD, Knepper JL. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet 2001;2:153-75. https://doi.org/10.1146/annurev.genom.2.1.153
  3. Gunay-Aygun M, Schwartz S, Heeger S, O'Riordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001;108:E92. https://doi.org/10.1542/peds.108.5.e92
  4. Bittel DC, Butler MG. Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology. Expert Rev Mol Med 2005;7:1-20.
  5. Cassidy SB. Prader-Willi syndrome. J Med Genet 1997;34:917-23. https://doi.org/10.1136/jmg.34.11.917
  6. Vogels A, Van Den Ende J, Keymolen K, Mortier G, Devriendt K, Legius E, et al. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet 2004;12:238-40. https://doi.org/10.1038/sj.ejhg.5201135
  7. Thomson AK, Glasson EJ, Bittles AH. A long-term population-based clinical and morbidity review of Prader-Willi syndrome in Western Australia. J Intellect Disabil Res 2006;50:69-78. https://doi.org/10.1111/j.1365-2788.2005.00770.x
  8. Whittington JE, Holland AJ, Webb T, Butler J, Clarke D, Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J Med Genet 2001;38:792-8. https://doi.org/10.1136/jmg.38.11.792
  9. Schrander-Stumpel CT, Curfs LM, Sastrowijoto P, Cassidy SB, Schrander JJ, Fryns JP. Prader-Willi syndrome: causes of death in an international series of 27 cases. Am J Med Genet A 2004;124A:333-8. https://doi.org/10.1002/ajmg.a.20371
  10. Eiholzer U. Deaths in children with Prader-Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS. Horm Res 2005;63:33-9. https://doi.org/10.1159/000082745
  11. Tauber M, Diene G, Molinas C, Hebert M. Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet A 2008;146:881-7.
  12. Trifiro G, Livieri C, Bosio L, Gargantini L, Corrias A, Pozzan G, et al. Neonatal hypotonia: don't forget the Prader-Willi syndrome. Acta Paediatr 2003;92:1085-9. https://doi.org/10.1111/j.1651-2227.2003.tb02582.x
  13. Bachere N, Diene G, Delagnes V, Molinas C, Moulin P, Tauber M. Early diagnosis and multidisciplinary care reduce the hospitalization time and duration of tube feeding and prevent early obesity in PWS infants. Horm Res 2008;69:45-52. https://doi.org/10.1159/000111795
  14. Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A 2007;143:443-8.
  15. Eiholzer U, Blum WF, Molinari L. Body fat determined by skinfold measurements is elevated despite underweight in infants with Prader- Labhart-Willi syndrome. J Pediatr 1999;134:222-5. https://doi.org/10.1016/S0022-3476(99)70419-1
  16. Bekx MT, Carrel AL, Shriver TC, Li Z, Allen DB. Decreased energy expenditure is caused by abnormal body composition in infants with Prader-Willi Syndrome. J Pediatr 2003;143:372-6. https://doi.org/10.1067/S0022-3476(03)00386-X
  17. Dykens EM, Hodapp RM, Walsh K, Nash LJ. Profiles, correlates, and trajectories of intelligence in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1992;31:1125-30. https://doi.org/10.1097/00004583-199211000-00022
  18. Curfs LM, Fryns JP. Prader-Willi syndrome: a review with special attention to the cognitive and behavioral profile. Birth Defects Orig Artic Ser 1992;28:99-104.
  19. Malich S, Largo RH, Schinzel A, Molinari L, Eiholzer U. Phenotypic heterogeneity of growth and psychometric intelligence in Prader-Willi syndrome: variable expression of a contiguous gene syndrome or parentchild resemblance? Am J Med Genet 2000;91:298-304. https://doi.org/10.1002/(SICI)1096-8628(20000410)91:4<298::AID-AJMG11>3.0.CO;2-G
  20. Zipf WB, Berntson GG. Characteristics of abnormal food-intake patterns in children with Prader-Willi syndrome and study of effects of naloxone. Am J Clin Nutr 1987;46:277-81. https://doi.org/10.1093/ajcn/46.2.277
  21. Holland AJ, Treasure J, Coskeran P, Dallow J. Characteristics of the eating disorder in Prader-Willi syndrome: implications for treatment. J Intellect Disabil Res 1995;39:373-81. https://doi.org/10.1111/j.1365-2788.1995.tb00541.x
  22. Nixon GM, Brouillette RT. Sleep and breathing in Prader-Willi syndrome. Pediatr Pulmonol 2002;34:209-17. https://doi.org/10.1002/ppul.10152
  23. Veltman MW, Craig EE, Bolton PF. Autism spectrum disorders in Prader- Willi and Angelman syndromes: a systematic review. Psychiatr Genet 2005;15:243-54. https://doi.org/10.1097/00041444-200512000-00006
  24. Wigren M, Hansen S. ADHD symptoms and insistence on sameness in Prader-Willi syndrome. J Intellect Disabil Res 2005;49:449-56. https://doi.org/10.1111/j.1365-2788.2005.00690.x
  25. Butler JV, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T. Prevalence of, and risk factors for, physical ill-health in people with Prader- Willi syndrome: a population-based study. Dev Med Child Neurol 2002;44:248-55. https://doi.org/10.1017/S001216220100202X
  26. Burman P, Ritzen EM, Lindgren AC. Endocrine dysfunction in Prader- Willi syndrome: a review with special reference to GH. Endocr Rev 2001;22:787-99. https://doi.org/10.1210/er.22.6.787
  27. Wollmann HA, Schultz U, Grauer ML, Ranke MB. Reference values for height and weight in Prader-Willi syndrome based on 315 patients. Eur J Pediatr 1998;157:634-42. https://doi.org/10.1007/s004310050901
  28. Hauffa BP, Schlippe G, Roos M, Gillessen-Kaesbach G, Gasser T. Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome. Acta Paediatr 2000;89:1302-11. https://doi.org/10.1111/j.1651-2227.2000.tb00755.x
  29. Schmidt H, Schwarz HP. Premature adrenarche, increased growth velocity and accelerated bone age in male patients with Prader-Labhart- Willi syndrome. Eur J Pediatr 2001;160:69-70. https://doi.org/10.1007/s004310000633
  30. Unanue N, Bazaes R, Iniguez G, Cortes F, Avila A, Mericq V. Adrenarche in Prader-Willi syndrome appears not related to insulin sensitivity and serum adiponectin. Horm Res 2007;67:152-8. https://doi.org/10.1159/000096742
  31. Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet 2009;17:3-13. https://doi.org/10.1038/ejhg.2008.165
  32. Glenn CC, Driscoll DJ, Yang TP, Nicholls RD. Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes. Mol Hum Reprod 1997;3:321-32. https://doi.org/10.1093/molehr/3.4.321
  33. Buiting K. Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C Semin Med Genet 2010;154C:365-76. https://doi.org/10.1002/ajmg.c.30273
  34. Amos-Landgraf JM, Ji Y, Gottlieb W, Depinet T, Wandstrat AE, Cassidy SB, et al. Chromosome breakage in the Prader-Willi and Angelman syndromes involves recombination between large, transcribed repeats at proximal and distal breakpoints. Am J Hum Genet 1999;65:370-86. https://doi.org/10.1086/302510
  35. Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T. Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics 2004;113:565-73. https://doi.org/10.1542/peds.113.3.565
  36. Christian SL, Robinson WP, Huang B, Mutirangura A, Line MR, Nakao M, et al. Molecular characterization of two proximal deletion breakpoint regions in both Prader-Willi and Angelman syndrome patients. Am J Hum Genet 1995;57:40-8.
  37. Bazeley PS, Shepelev V, Talebizadeh Z, Butler MG, Fedorova L, Filatov V, et al. snoTARGET shows that human orphan snoRNA targets locate close to alternative splice junctions. Gene 2008;408:172-9. https://doi.org/10.1016/j.gene.2007.10.037
  38. Cavaille J, Buiting K, Kiefmann M, Lalande M, Brannan CI, Horsthemke B, et al. Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. Proc Natl Acad Sci U S A 2000;97:14311-6. https://doi.org/10.1073/pnas.250426397
  39. Kishore S, Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006;311:230-2. https://doi.org/10.1126/science.1118265
  40. Gray TA, Saitoh S, Nicholls RD. An imprinted, mammalian bicistronic transcript encodes two independent proteins. Proc Natl Acad Sci U S A 1999;96:5616-21. https://doi.org/10.1073/pnas.96.10.5616
  41. Ozcelik T, Leff S, Robinson W, Donlon T, Lalande M, Sanjines E, et al. Small nuclear ribonucleoprotein polypeptide N (SNRPN), an expressed gene in the Prader-Willi syndrome critical region. Nat Genet 1992;2:265-9. https://doi.org/10.1038/ng1292-265
  42. de Smith AJ, Purmann C, Walters RG, Ellis RJ, Holder SE, Van Haelst MM, et al. A deletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum Mol Genet 2009;18:3257-65. https://doi.org/10.1093/hmg/ddp263
  43. Runte M, Varon R, Horn D, Horsthemke B, Buiting K. Exclusion of the C/D box snoRNA gene cluster HBII-52 from a major role in Prader-Willi syndrome. Hum Genet 2005;116:228-30. https://doi.org/10.1007/s00439-004-1219-2
  44. Sahoo T, del Gaudio D, German JR, Shinawi M, Peters SU, Person RE, et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat Genet 2008;40:719-21. https://doi.org/10.1038/ng.158
  45. Butler MG, Fischer W, Kibiryeva N, Bittel DC. Array comparative genomic hybridization (aCGH) analysis in Prader-Willi syndrome. Am J Med Genet A 2008;146:854-60.
  46. Sahoo T, Bacino CA, German JR, Shaw CA, Bird LM, Kimonis V, et al. Identification of novel deletions of 15q11q13 in Angelman syndrome by array-CGH: molecular characterization and genotype-phenotype correlations. Eur J Hum Genet 2007;15:943-9. https://doi.org/10.1038/sj.ejhg.5201859
  47. Sahoo T, Shaw CA, Young AS, Whitehouse NL, Schroer RJ, Stevenson RE, et al. Array-based comparative genomic hybridization analysis of recurrent chromosome 15q rearrangements. Am J Med Genet A 2005;139A:106-13. https://doi.org/10.1002/ajmg.a.31000
  48. Buiting K, Gross S, Lich C, Gillessen-Kaesbach G, el-Maarri O, Horsthemke B. Epimutations in Prader-Willi and Angelman syndromes: a molecular study of 136 patients with an imprinting defect. Am J Hum Genet 2003;72:571-7. https://doi.org/10.1086/367926
  49. Glenn CC, Saitoh S, Jong MT, Filbrandt MM, Surti U, Driscoll DJ, et al. Gene structure, DNA methylation, and imprinted expression of the human SNRPN gene. Am J Hum Genet 1996;58:335-46.
  50. Kubota T, Das S, Christian SL, Baylin SB, Herman JG, Ledbetter DH. Methylation-specific PCR simplifies imprinting analysis. Nat Genet 1997;16:16-7. https://doi.org/10.1038/ng0597-16
  51. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M; speakers contributors at the Second Expert Meeting of the Comprehensive Care of Patients with PWS. Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-97. https://doi.org/10.1210/jc.2008-0649
  52. Lee PDK. Endocrine and metabolic aspects of Prader-willi syndrome. In: Greenswag LR, Alexander RC, editors. Management of Prader-willi Syndrome. 2nd ed. New York: Springer-Verlag, 1995:132-57.
  53. Miller J, Silverstein J, Shuster J, Driscoll DJ, Wagner M. Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome. J Clin Endocrinol Metab 2006;91:413-7. https://doi.org/10.1210/jc.2005-1279
  54. Pandey SN, Vaidya RA, Irani A. Growth hormone treatment in a girl with Prader Willi syndrome. Indian J Pediatr 2003;70:351-3. . https://doi.org/10.1007/BF02723593
  55. Mogul HR, Lee PDK, Whitman BY, Zipf WB, Frey M, Myers S, et al. Growth hormone (GH) improves lean body mass (LBM) without glucose impairment in growth hormone deficient (GHD) Prader-Willi Syndrome (PWS) adults: Results from the US Multicenter Trial. 88th Annual Meeting of the Endocrine Society, Boston 2006.
  56. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-5. https://doi.org/10.1210/jc.87.4.1581
  57. Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab 2010;95:1131-6. https://doi.org/10.1210/jc.2009-1389
  58. I'Allemand UEaSMaD. Does growth hormone therapy improve motor development in infants with Prader-Willi syndrome? Eur J Pediatr 2000;159:299-301. https://doi.org/10.1007/s004310050075
  59. Eiholzer U. Prader-Willi Syndrome: effects of human growth hormone treatment. Zurich, Switzerland: Karger, 2001.
  60. Eiholzer U, L'Allemand D, Schlumpf M, Rousson V, Gasser T, Fusch C. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome. J Pediatr 2004;144:753-8.
  61. Eiholzer U, Malich S, I'Allemand D. Does growth hormone therapy improve motor development in infants with Prader-Willi syndrome? Eur J Pediatr 2000;159:299. https://doi.org/10.1007/s004310050075
  62. Festen DA, Wevers M, Lindgren AC, Bohm B, Otten BJ, Wit JM, et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol (Oxf) 2008;68:919-25. https://doi.org/10.1111/j.1365-2265.2007.03126.x
  63. Adem A, Jossan SS, d'Argy R, Gillberg PG, Nordberg A, Winblad B, et al. Insulin-like growth factor 1 (IGF-1) receptors in the human brain: quantitative autoradiographic localization. Brain Res 1989;503:299-303. https://doi.org/10.1016/0006-8993(89)91678-8
  64. Gale CR, O'Callaghan FJ, Godfrey KM, Law CM, Martyn CN. Critical periods of brain growth and cognitive function in children. Brain 2004;127:321-9. https://doi.org/10.1093/brain/awh034
  65. Nolte W, Rädisch C, Rodenbeck A, Wiltfang J, Hüfner M. Polysomnographic findings in five adult patients with pituitary insufficiency before and after cessation of human growth hormone replacement therapy. Clin Endocrinol (Oxf) 2002;56:805-10. https://doi.org/10.1046/j.1365-2265.2002.01531.x
  66. Haqq AM, Stadler DD, Jackson RH, Rosenfield RG, Purnell JQ, LaFranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab 2003;88:2206-12. https://doi.org/10.1210/jc.2002-021536
  67. Wilson SS, Cotterill AM, Harris MA. Growth hormone and respiratory compromise in Prader-Willi Syndrome. Arch Dis Child 2006;91:349-50. https://doi.org/10.1136/adc.2005.086090
  68. Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson Wikland K, et al. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database). Clin Endocrinol (Oxf) 2006;65:178-85. https://doi.org/10.1111/j.1365-2265.2006.02570.x
  69. Wharton RH, Wang T, Graeme-Cook F, Briggs S, Cole RE. Acute idiopathic gastric dilation with gastric necrosis in individuals with Prader-Willi syndrome. Am J Med Genet 1997;73:437-41. https://doi.org/10.1002/(SICI)1096-8628(19971231)73:4<437::AID-AJMG12>3.0.CO;2-S

Cited by

  1. Epigenetics Lights Up the Obesity Field vol.4, pp.3, 2011, https://doi.org/10.1159/000329847
  2. A short clinical overview of Prader-Willi syndrome : Clinical aspects of PWS vol.1, pp.4, 2011, https://doi.org/10.1111/j.1758-8111.2011.00022.x
  3. Ontogeny of growth-regulating genes in the placenta vol.33, pp.2, 2011, https://doi.org/10.1016/j.placenta.2011.11.018
  4. Testosterone replacement therapy to improve secondary sexual characteristics and body composition without adverse behavioral problems in adult male patients with Prader–Willi syndrome: An observ vol.161, pp.9, 2011, https://doi.org/10.1002/ajmg.a.36048
  5. HYPERCAPNEA AND NON INVASIVE VENTILATION IN PRADER-WILLI SYNDROME vol.10, pp.4, 2013, https://doi.org/10.7199/ped.oncall.2013.53
  6. Clinical and genetic features of Prader-Willi syndrome in China vol.173, pp.1, 2011, https://doi.org/10.1007/s00431-013-2124-2
  7. Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities vol.19, pp.3, 2011, https://doi.org/10.1038/mp.2013.42
  8. Disease‐specific growth charts for Korean infants with Prader–Willi syndrome vol.167, pp.1, 2015, https://doi.org/10.1002/ajmg.a.36816
  9. Growth hormone improves short stature in children with Diamond‐Blackfan anemia vol.62, pp.3, 2011, https://doi.org/10.1002/pbc.25341
  10. Quality of Life in Prader-Willi Syndrome Patients vol.1, pp.2, 2015, https://doi.org/10.19125/jmrd.2015.1.2.60
  11. Microdeletion syndromes and psychiatry: an update vol.23, pp.3, 2011, https://doi.org/10.1192/apt.bp.114.012864
  12. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome vol.3, pp.12, 2011, https://doi.org/10.1172/jci.insight.98333
  13. Floppy neonate with feeding difficulties vol.104, pp.3, 2019, https://doi.org/10.1136/archdischild-2017-314517
  14. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study vol.32, pp.8, 2019, https://doi.org/10.1515/jpem-2018-0539
  15. Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study vol.32, pp.8, 2019, https://doi.org/10.1515/jpem-2018-0539
  16. Small Nuclear Ribonucleoprotein Polypeptide N Accelerates Malignant Progression and Poor Prognosis in Colorectal Cancer Transcriptionally Regulated by E2F8 vol.10, pp.None, 2011, https://doi.org/10.3389/fonc.2020.561287
  17. Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial vol.137, pp.None, 2021, https://doi.org/10.1016/j.jpsychires.2020.11.006
  18. Pitolisant in an Adolescent with Prader-Willi Syndrome vol.26, pp.4, 2011, https://doi.org/10.5863/1551-6776-26.4.405